Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

60614

registered interest
date	09/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions his Department has had with Public Health England over a possible nationawide roll-out of the recent Be Clear on Cancer pilot study for oesophago-gastric cancer in the North East.
tabling member constituency	Ashton-under-Lyne
tabling member printed	David Heyes
uin	199746
answer	answer is ministerial correction date of answer 16/06/2014 answer text <p /> <p /> <p>We want to lead the world in cancer care and are investing over £750 million, over four years up till 2014-15, including £450 million in the early diagnosis of cancer, including oesophago-gastric cancers.</p><p> </p><p>The earlier diagnosis money is designed to support earlier diagnosis of cancer by improving public awareness of cancer signs and symptoms through centrally funded Be Clear on Cancer campaigns; increasing general practitioner access to key diagnostic tests; and, to pay for extra testing and treatment in secondary care.</p><p> </p><p>Be Clear on Cancercampaigns are tested at a local and regional level, before a decision is taken on whether to run them nationally throughout England. Following a local pilot which ran from April to July 2012, we ran a regional Be Clear on Cancer pilot campaign from 10 February to 9 March 2014 raising awareness of the signs and symptoms of oesophago-gastric cancer in the North East and North Cumbria. The campaign included television, radio, press and outdoor advertising. The findings of this pilot are being evaluated by Public Health England, who works closely with the Department and NHS England to ensure that health care professionals are targeted with campaign information to encourage earlier diagnoses and referrals, before a decision is taken on whether to roll out the campaign nationally throughout England.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 16/06/2014 16:16:11 answering member 3918 label Biography information for Jane Ellison
tabling member	1386 label Biography information for David Heyes

60635

registered interest
date	09/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Parkinson's Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to improve patient choice and reduce avoidable harm for people with advanced Parkinson's.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	199567
answer	answer is ministerial correction date of answer 16/06/2014 answer text <p>From April 2013, NHS England assumed responsibility for commissioning adult specialist neurosciences services, including the majority of services for patients with Parkinson's disease, with some being the responsibility of clinical commissioning groups.</p><p> </p><p>NHS England has advised that it does not routinely fund Duodopa (co-careldopa) for the treatment of Parkinson's disease. Clinicians can submit individual funding requests for this treatment on behalf of their patients as per NHS England's individual funding requests standard operating procedure, which is found at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/04/cp-04.pdf</p><p> </p><p>NHS England has advised that its individual funding request process is monitored against the standard operating procedure to ensure that referring clinicians are informed of outcomes in a timely manner.</p><p><strong> </strong></p><p>Treatments for Parkinson's are largely drug based and there is a choice of therapies available. <em> Parkinson's disease: Diagnosis and management in primary and secondary care</em>, published by the National Institute for Health and Care Excellence in 2006, makes it clear that communication with people with Parkinson's disease should be aimed towards empowering them to participate in the judgements and choices about their own care. With regard to decisions about the drugs available for treatment of the disease in its later stages, the guidance states that the patient preference should be taken into account, once they have been informed of the short- and long-term benefits and drawbacks of the different types of drugs available.</p><p> </p><p>To reduce avoidable harm, through the Mandate we have asked NHS England to make measurable progress by 2015 to embed a culture of patient safety in the NHS including through improved reporting of incidents. The NHS Outcomes Framework contains a range of indicators designed to measure progress in this area of care which will be relevant to patients with all conditions, including, Parkinson's disease.</p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 199571 question first answered 16/06/2014 13:35:35 answering member 1439 label Biography information for Norman Lamb
tabling member	394 label Biography information for Mr Clive Betts

60636

registered interest
date	09/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Parkinson's Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to prevent unnecessary delays in the prescription of Duodopa for people with Parkinson's.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	199571
answer	answer is ministerial correction date of answer 16/06/2014 answer text <p>From April 2013, NHS England assumed responsibility for commissioning adult specialist neurosciences services, including the majority of services for patients with Parkinson's disease, with some being the responsibility of clinical commissioning groups.</p><p> </p><p>NHS England has advised that it does not routinely fund Duodopa (co-careldopa) for the treatment of Parkinson's disease. Clinicians can submit individual funding requests for this treatment on behalf of their patients as per NHS England's individual funding requests standard operating procedure, which is found at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/04/cp-04.pdf</p><p> </p><p>NHS England has advised that its individual funding request process is monitored against the standard operating procedure to ensure that referring clinicians are informed of outcomes in a timely manner.</p><p><strong> </strong></p><p>Treatments for Parkinson's are largely drug based and there is a choice of therapies available. <em> Parkinson's disease: Diagnosis and management in primary and secondary care</em>, published by the National Institute for Health and Care Excellence in 2006, makes it clear that communication with people with Parkinson's disease should be aimed towards empowering them to participate in the judgements and choices about their own care. With regard to decisions about the drugs available for treatment of the disease in its later stages, the guidance states that the patient preference should be taken into account, once they have been informed of the short- and long-term benefits and drawbacks of the different types of drugs available.</p><p> </p><p>To reduce avoidable harm, through the Mandate we have asked NHS England to make measurable progress by 2015 to embed a culture of patient safety in the NHS including through improved reporting of incidents. The NHS Outcomes Framework contains a range of indicators designed to measure progress in this area of care which will be relevant to patients with all conditions, including, Parkinson's disease.</p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 199567 question first answered 16/06/2014 13:35:35 answering member 1439 label Biography information for Norman Lamb
tabling member	394 label Biography information for Mr Clive Betts

60637

registered interest
date	09/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Continuing Care
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to ensure that the Clinical Priorities Advisory Group takes account of evidence from (a) patients, (b) clinicians and (c) patient groups when making decisions on the availability of treatments for progressive conditions.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	199558
answer	answer is ministerial correction date of answer 16/06/2014 answer text <p>NHS England has advised that the Clinical Priorities Advisory Group (CPAG) is an advisory group and not a decision making body. It considers policy and makes recommendations to the Directly Commissioned Services Committee who make the final decisions on NHS England's commissioning position.</p><p> </p><p>The Group's membership includes four Patient and Public Voice members and senior clinicians from NHS England. The policies that are presented to CPAG for consideration are developed by Clinical Reference Groups (CRGs) who are made up of patients, clinicians, and key stakeholders including patient groups. These members are involved in the development of policies.</p><p> </p><p>Prior to submission of any documents to CPAG, a two week stakeholder testing phase is undertaken where registered CRG stakeholders including clinicians, patients, and patient groups, as well as industry, have an opportunity to make comments. These are considered as well as the evidence base for the policy by CPAG.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 16/06/2014 14:32:45 answering member 3918 label Biography information for Jane Ellison
tabling member	394 label Biography information for Mr Clive Betts

60646

registered interest
date	09/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cystic Fibrosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure that high-cost drugs are delivered to cystic fibrosis patients on time.
tabling member constituency	Colne Valley
tabling member printed	Jason McCartney
uin	199708
answer	answer is ministerial correction date of answer 16/06/2014 answer text <p>It is important that patients, including those with cystic fibrosis, get those high cost drugs provided through homecare services on time.</p><p> </p><p>The Department commissioned a review of homecare medicine supply arrangements to ensure they deliver the best value for patients, the National Health Service and the provider market. The review report, <em>Homecare Medicines: </em><em>Towards a Vision for the Future,</em> was published in December 2011 and is available at:</p><p> </p><p>http://media.dh.gov.uk/network/121/files/2011/12/111201-Homecare-Medicines-Towards-a-Vision-for-the-Future2.pdf</p><p> </p><p>The outcome of subsequent improvement work is summarised in the further report, <em>Homecare Medicines: Towards a Vision for the Future - Taking Forward the Recommendations</em>, published in May 2014 and available at:</p><p> </p><p>www.uhns.nhs.uk/AboutUs/NHSHomecareMedicinesinEngland.aspx</p><p> </p><p>NHS England issued a patient safety alert on minimising the risks of omitted and delayed medicines for patients receiving homecare services on 10 April 2014. This recommended that all healthcare organisations that commission clinical homecare services:</p><p>- establish if medicine homecare services were used by their organisation and if incidents of omitted and delayed medicines had occurred;</p><p>- consider whether immediate action needed to be taken locally and, if required, develop an action plan, to reduce risk and the potential risk to patients;</p><p>- disseminate the alert to all medical, nursing, pharmacy and other staff involved in the care of homecare patients; and</p><p>- report patient safety incidents concerning homecare to the National Reporting and Learning Service.</p><p> </p><p>A copy of the patient safety alert is available at:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2014/04/psa-omitted-delayed-meds.pdf</p><p> </p><p>The Department continues to work with NHS England, homecare companies, pharmaceutical suppliers and the NHS to ensure that homecare arrangements are safe and deliver value for the NHS and improved outcomes for patients.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter grouped question UIN 199709 question first answered 16/06/2014 13:15:27 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	3953 label Biography information for Jason McCartney

60647

registered interest
date	09/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Home Care Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent assessment he has made of the effectiveness of the commissioning of homecare services by the NHS.
tabling member constituency	Colne Valley
tabling member printed	Jason McCartney
uin	199709
answer	answer is ministerial correction date of answer 16/06/2014 answer text <p>It is important that patients, including those with cystic fibrosis, get those high cost drugs provided through homecare services on time.</p><p> </p><p>The Department commissioned a review of homecare medicine supply arrangements to ensure they deliver the best value for patients, the National Health Service and the provider market. The review report, <em>Homecare Medicines: </em><em>Towards a Vision for the Future,</em> was published in December 2011 and is available at:</p><p> </p><p>http://media.dh.gov.uk/network/121/files/2011/12/111201-Homecare-Medicines-Towards-a-Vision-for-the-Future2.pdf</p><p> </p><p>The outcome of subsequent improvement work is summarised in the further report, <em>Homecare Medicines: Towards a Vision for the Future - Taking Forward the Recommendations</em>, published in May 2014 and available at:</p><p> </p><p>www.uhns.nhs.uk/AboutUs/NHSHomecareMedicinesinEngland.aspx</p><p> </p><p>NHS England issued a patient safety alert on minimising the risks of omitted and delayed medicines for patients receiving homecare services on 10 April 2014. This recommended that all healthcare organisations that commission clinical homecare services:</p><p>- establish if medicine homecare services were used by their organisation and if incidents of omitted and delayed medicines had occurred;</p><p>- consider whether immediate action needed to be taken locally and, if required, develop an action plan, to reduce risk and the potential risk to patients;</p><p>- disseminate the alert to all medical, nursing, pharmacy and other staff involved in the care of homecare patients; and</p><p>- report patient safety incidents concerning homecare to the National Reporting and Learning Service.</p><p> </p><p>A copy of the patient safety alert is available at:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2014/04/psa-omitted-delayed-meds.pdf</p><p> </p><p>The Department continues to work with NHS England, homecare companies, pharmaceutical suppliers and the NHS to ensure that homecare arrangements are safe and deliver value for the NHS and improved outcomes for patients.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter grouped question UIN 199708 question first answered 16/06/2014 13:15:27 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	3953 label Biography information for Jason McCartney

60675

registered interest
date	09/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Maternity Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what savings are planned for neonatal care under the Quality, Innovation, Productivity and Prevention Initiative for 2014-15.
tabling member constituency	Daventry
tabling member printed	Chris Heaton-Harris
uin	199591
answer	answer is ministerial correction date of answer 16/06/2014 answer text <p>NHS England, as part of its direct commissioning responsibilities for specialised services, has an ongoing programme in place to identify both local and national opportunities to identify potential efficiencies as part of its management and prioritisation of available resources.</p><p> </p><p>NHS England's Clinical Reference Groups (CRGs), involving lead clinical, patient and professional representatives, are assisting NHS England in this work, particularly in respect of proposals that might be considered nationwide.</p><p> </p><p>Specialised neonatal care is one of NHS England's most significant areas of expenditure and the Neonatal CRG has therefore been involved in identifying potential neonatal specific schemes, which may have the potential to deliver savings whilst maintaining safety and quality. The schemes will be subject to a confirm and challenge process to determine their deliverability, before being worked up into schemes which could be implemented on a national basis.</p><p> </p><p>It is therefore not possible, at this stage in the programme's development, to quantify the level of savings that might be generated nationally or the specific savings approach that will be adopted.</p><p> </p><p>It is unlikely that the national schemes currently being considered will generate savings in 20140-15. The schemes are more likely to be transformational in design and therefore are more likely to deliver savings in the longer term.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter grouped question UIN 199592 question first answered 16/06/2014 12:58:45 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	3977 label Biography information for Chris Heaton-Harris

60676

registered interest
date	09/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Maternity Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how the Quality, Innovation, Productivity and Prevention savings for neonatal care will be realised.
tabling member constituency	Daventry
tabling member printed	Chris Heaton-Harris
uin	199592
answer	answer is ministerial correction date of answer 16/06/2014 answer text <p>NHS England, as part of its direct commissioning responsibilities for specialised services, has an ongoing programme in place to identify both local and national opportunities to identify potential efficiencies as part of its management and prioritisation of available resources.</p><p> </p><p>NHS England's Clinical Reference Groups (CRGs), involving lead clinical, patient and professional representatives, are assisting NHS England in this work, particularly in respect of proposals that might be considered nationwide.</p><p> </p><p>Specialised neonatal care is one of NHS England's most significant areas of expenditure and the Neonatal CRG has therefore been involved in identifying potential neonatal specific schemes, which may have the potential to deliver savings whilst maintaining safety and quality. The schemes will be subject to a confirm and challenge process to determine their deliverability, before being worked up into schemes which could be implemented on a national basis.</p><p> </p><p>It is therefore not possible, at this stage in the programme's development, to quantify the level of savings that might be generated nationally or the specific savings approach that will be adopted.</p><p> </p><p>It is unlikely that the national schemes currently being considered will generate savings in 20140-15. The schemes are more likely to be transformational in design and therefore are more likely to deliver savings in the longer term.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter grouped question UIN 199591 question first answered 16/06/2014 12:58:45 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	3977 label Biography information for Chris Heaton-Harris

60677

registered interest
date	09/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Maternity Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how the money allocated by his Department to improve birthing environments was spent in (a) 2012-13 and (b) 2013-14.
tabling member constituency	Daventry
tabling member printed	Chris Heaton-Harris
uin	199589
answer	answer is ministerial correction date of answer 16/06/2014 answer text <p>Information on the breakdown of the money allocated by the Department to improve birthing environments in 2012-13 and 2013-14 has been placed in the Library.</p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 16/06/2014 14:49:46 answering member 3932 label Biography information for Dr Dan Poulter attachment 1 file name Maternity_Capital_Funding_Allocations_2012-13_and_2013-14.pdf title Maternity Capital Funding Allocations 2012-14
tabling member	3977 label Biography information for Chris Heaton-Harris

60678

registered interest
date	09/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Maternity Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions his Department has had with NHS England about ensuring that all trusts provide the necessary facilities and support to ensure that families can be with their babies while they are in neonatal care, as set out in the national service specification for neonatal critical care.
tabling member constituency	Daventry
tabling member printed	Chris Heaton-Harris
uin	199590
answer	answer is ministerial correction date of answer 16/06/2014 answer text <p>The Department and NHS England regularly discuss maternity and newborn care.</p><p> </p><p>NHS England's Neonatal Service Specification requires that all commissioned providers of Neonatal Services provide appropriate family facilities. The current service specification states that:</p><p> </p><p>Facilities should be available to support family centred care including access to parent accommodation, private and comfortable breastfeeding/expressing facilities, and private room for confidential conversations and so on.</p><p> </p><p>A revised specification has recently been drafted, within which this statement has been strengthened. The revised draft specification has been out to public consultation and the Clinical Reference Group is currently responding to the comments received. It is anticipated that the revised service specification will be included in NHS England contracts with providers from April 2015.</p><p> </p><p>As part of NHS England's Service Specification Compliance process, all units will have assessed their level of compliance against the service specification. Where relevant, units will have highlighted where they are not yet meeting this requirement. In those circumstances, the Area Team Commissioner and the relevant provider will have agreed an action plan for achievement of the standard, where is it not currently being met, within 12 months. The actual facilities provided for families are locally determined and the exact number of overnight beds may therefore vary from service to service.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 16/06/2014 12:50:02 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	3977 label Biography information for Chris Heaton-Harris